ATE369421T1 - Genetische abschaffung und austausch - Google Patents
Genetische abschaffung und austauschInfo
- Publication number
- ATE369421T1 ATE369421T1 AT97915579T AT97915579T ATE369421T1 AT E369421 T1 ATE369421 T1 AT E369421T1 AT 97915579 T AT97915579 T AT 97915579T AT 97915579 T AT97915579 T AT 97915579T AT E369421 T1 ATE369421 T1 AT E369421T1
- Authority
- AT
- Austria
- Prior art keywords
- gene
- replacement
- nucleic acids
- suppressing
- cdna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9606961.2A GB9606961D0 (en) | 1996-04-02 | 1996-04-02 | Genetic strategy III |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE369421T1 true ATE369421T1 (de) | 2007-08-15 |
Family
ID=10791494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97915579T ATE369421T1 (de) | 1996-04-02 | 1997-04-02 | Genetische abschaffung und austausch |
Country Status (10)
Country | Link |
---|---|
US (2) | US7138378B1 (de) |
EP (1) | EP0891423B1 (de) |
AT (1) | ATE369421T1 (de) |
AU (1) | AU728785B2 (de) |
CA (1) | CA2251696C (de) |
DE (1) | DE69737992T2 (de) |
ES (1) | ES2292185T3 (de) |
GB (1) | GB9606961D0 (de) |
NZ (1) | NZ332586A (de) |
WO (1) | WO1997037014A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030069195A1 (en) * | 1996-03-01 | 2003-04-10 | Farrar Gwenyth Jane | Suppression of polymorphic alleles |
GB9606961D0 (en) * | 1996-04-02 | 1996-06-05 | Farrar Gwyneth J | Genetic strategy III |
US20040234999A1 (en) * | 1996-04-02 | 2004-11-25 | Farrar Gwenyth Jane | Genetic suppression and replacement |
US8551970B2 (en) * | 1996-04-02 | 2013-10-08 | Optigen Patents Limited | Genetic suppression and replacement |
US6303848B1 (en) | 1998-01-16 | 2001-10-16 | Large Scale Biology Corporation | Method for conferring herbicide, pest, or disease resistance in plant hosts |
US6426185B1 (en) | 1998-01-16 | 2002-07-30 | Large Scale Biology Corporation | Method of compiling a functional gene profile in a plant by transfecting a nucleic acid sequence of a donor plant into a different host plant in an anti-sense orientation |
NZ733844A (en) | 2015-02-26 | 2022-07-01 | Ionis Pharmaceuticals Inc | Allele specific modulators of p23h rhodopsin |
US11118185B2 (en) | 2016-03-01 | 2021-09-14 | University Of Florida Research Foundation, Incorporated | AAV vectors for treatment of dominant retinitis pigmentosa |
WO2021174168A1 (en) * | 2020-02-28 | 2021-09-02 | Blueallele, Llc | Methods for treating gain-of-function disorders combining gene editing and gene therapy |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
JPH0376580A (ja) | 1989-08-17 | 1991-04-02 | Japan Tobacco Inc | 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法 |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5223391A (en) | 1990-02-21 | 1993-06-29 | President And Fellows Of Harvard College | Inhibitors of herpes simplex virus replication |
US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
NO312681B1 (no) | 1990-08-24 | 2002-06-17 | Univ California | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
JPH06504443A (ja) | 1991-01-04 | 1994-05-26 | ワシントン ユニヴァーシティ | 孤立性脆弱x症候群に関するdna配列 |
DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
JP3002292B2 (ja) * | 1991-06-10 | 2000-01-24 | シャープ株式会社 | 画像調整装置 |
EP0590082B1 (de) | 1991-06-14 | 1999-10-27 | Isis Pharmaceuticals, Inc. | Antisense-oligonukleotid-inhibition des ras-gen |
AU3274793A (en) | 1991-12-12 | 1993-07-19 | Hybritech Incorporated | Enzymatic inverse polymerase chain reaction library mutagenesis |
IL101600A (en) | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US6107062A (en) | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
JPH08503366A (ja) | 1992-11-09 | 1996-04-16 | トーマス・ジェファーソン・ユニバーシティ | コラーゲンの突然変異および野生型遺伝子の発現を阻害するアンチセンスオリゴヌクレオチド |
CA2159195A1 (en) | 1993-03-26 | 1994-10-13 | Darwin J. Prockop | Use of a col 1a1 mini-gene construct to inhibit collagen synthesis |
ES2290951T3 (es) | 1993-05-11 | 2008-02-16 | The University Of North Carolina At Chapel Hill | Oligonucleotidos antisentido que combaten el corte y empalme aberrante y metodos de uso de los mismos. |
US5702890A (en) | 1993-07-26 | 1997-12-30 | K.O. Technology, Inc. | Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
US6025127A (en) * | 1994-01-14 | 2000-02-15 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection in histologic tissue |
US5834440A (en) | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
WO1995034573A1 (en) | 1994-06-03 | 1995-12-21 | Brigham And Women's Hospital | Identification of polycystic kidney disease gene, diagnostics and treatment |
US5807718A (en) * | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
US6482803B1 (en) * | 1995-09-01 | 2002-11-19 | Board Of Regents, The University Of Texas System | Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A |
GB9519299D0 (en) | 1995-09-21 | 1995-11-22 | Farrar Gwyneth J | Genetic strategy |
GB9604449D0 (en) | 1996-03-01 | 1996-05-01 | Farrar Gwyneth J | Genetic strategy ii |
GB9606961D0 (en) * | 1996-04-02 | 1996-06-05 | Farrar Gwyneth J | Genetic strategy III |
AU3206697A (en) | 1996-05-17 | 1997-12-09 | Thomas Jefferson University | Ribozyme-mediated gene replacement |
US5977391A (en) * | 1996-08-29 | 1999-11-02 | Arzneimittelwerk Dresden Gmbh | (+)- and (-) -8-halogen-6- hydroxy-octanoic acid its salts and esters and process for making |
US5814500A (en) | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
-
1996
- 1996-04-02 GB GBGB9606961.2A patent/GB9606961D0/en active Pending
-
1997
- 1997-04-02 AU AU23007/97A patent/AU728785B2/en not_active Expired
- 1997-04-02 CA CA002251696A patent/CA2251696C/en not_active Expired - Lifetime
- 1997-04-02 DE DE69737992T patent/DE69737992T2/de not_active Expired - Lifetime
- 1997-04-02 US US09/155,708 patent/US7138378B1/en not_active Expired - Fee Related
- 1997-04-02 NZ NZ332586A patent/NZ332586A/xx not_active IP Right Cessation
- 1997-04-02 WO PCT/GB1997/000929 patent/WO1997037014A1/en active IP Right Grant
- 1997-04-02 AT AT97915579T patent/ATE369421T1/de not_active IP Right Cessation
- 1997-04-02 EP EP97915579A patent/EP0891423B1/de not_active Expired - Lifetime
- 1997-04-02 ES ES97915579T patent/ES2292185T3/es not_active Expired - Lifetime
-
2005
- 2005-09-12 US US11/224,524 patent/US20060128648A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU728785B2 (en) | 2001-01-18 |
CA2251696A1 (en) | 1997-10-09 |
EP0891423B1 (de) | 2007-08-08 |
AU2300797A (en) | 1997-10-22 |
GB9606961D0 (en) | 1996-06-05 |
US20060128648A1 (en) | 2006-06-15 |
DE69737992T2 (de) | 2008-04-24 |
ES2292185T3 (es) | 2008-03-01 |
NZ332586A (en) | 2000-07-28 |
CA2251696C (en) | 2009-06-23 |
US7138378B1 (en) | 2006-11-21 |
DE69737992D1 (de) | 2007-09-20 |
EP0891423A1 (de) | 1999-01-20 |
WO1997037014A1 (en) | 1997-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2294516A1 (en) | Ikk-.beta. proteins, nucleic acids and methods | |
MXPA03002218A (es) | Peptidos antimicrobianos y metodos de uso. | |
HK1026229A1 (en) | Modified dorsal tissue affecting factor and compositions | |
WO2000026368A3 (en) | Therapeutic antiangiogenic endostatin compositions | |
WO1999054461A3 (de) | Menschliche nukleinsäuresequenzen aus endometriumtumorgewebe | |
WO1999055858A3 (de) | Menschliche nukleinsäuresequenzen aus pankreastumorgewebe | |
ATE293700T1 (de) | Adenovirus mit glutathion peroxydate gene | |
ATE369421T1 (de) | Genetische abschaffung und austausch | |
CA2281895A1 (en) | Ikb kinases | |
CA2294566A1 (en) | Ikk-.alpha. proteins, nucleic acids and methods | |
CA2281206A1 (en) | Geranyl diphosphate synthase genes | |
GB9604449D0 (en) | Genetic strategy ii | |
CA2253006A1 (en) | .beta.-carotene hydroxylase gene | |
CA2204512A1 (en) | Lgmd gene coding for a calcium dependent protease | |
CA2340934A1 (en) | Novel collectin | |
WO2000055193A3 (en) | Human dan/cerberus related protein 6 (dcr6) | |
CA2192260A1 (en) | Dna fragment encoding a protein involved in fatty aldehyde decarbonylase activity, recombinant molecules comprising said fragment and a method for obtaining transformed bacterial cells and plants | |
FR2792651A1 (fr) | Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations | |
AR013801A1 (es) | Nuevas moleculas de acido nucleico aislada, una proteina de epoxido hidrolasa de artropodo hematofago aislada, una formulacion de proteinas deepoxido hidrolasa de pulga, una composicion terapeutica que reduce la infestacion de ectoparasitos hematofagos; uso de dicha composicion para la | |
EP1065269A4 (de) | Für hm1.24 antigen kodierendes gen und dessen promotor | |
WO2002064802A3 (en) | Regulatory genes suitable for use in gene expression | |
WO1999054446A3 (de) | Menschliche nukleinsäuresequenzen, die in pankreasnormalgewebe überexprimiert sind | |
CA2302828A1 (en) | Sequence-determined dna fragments and corresponding polypeptides encoded thereby | |
MY115796A (en) | Base sequence of the coat protein gene of papaya leaf- distortion mosaic virus | |
AU2558392A (en) | Ribosomal structure derived from the genomic rna structure of the delta hepatitus virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |